Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention

Cesare Cuspidi, Francesca Negri, Alberto Zanchetti

Research output: Contribution to journalArticle

Abstract

Left ventricular hypertrophy (LVH) and atrial fibrillation (AF) are strong predictors of cardiovascular (CV) morbidity and mortality, independently of blood pressure levels and other modifiable and nonmodifiable risk factors. The actions of circulating and tissue angiotensin II, mediated by AT1 receptors, play an important role in the development of a wide spectrum of cardiovascular alterations, including LVH, atrial enlargement and AF. Growing experimental and clinical evidence suggests that antihypertensive drugs may exert different effects on LVH regression and new onset AF in the setting of arterial hypertension. Since a number of large and adequately designed studies have found angiotensin II receptor blockers (ARBs) to be more effective in reducing LVH than beta-blockers and data are also available showing their effectiveness in preventing new or recurrent AF, it is reasonable to consider this class of drugs among first line therapies in patients with hypertension and LVH (a very high risk phenotype predisposing to AF) and as adjunctive therapy to antiarrhythmic agents in patients undergoing pharmacological or electrical cardioversion of AF.

Original languageEnglish
Pages (from-to)67-73
Number of pages7
JournalVascular Health and Risk Management
Volume4
Issue number1
DOIs
Publication statusPublished - 2008

Fingerprint

Angiotensin Receptor Antagonists
Left Ventricular Hypertrophy
Atrial Fibrillation
Hypertension
Electric Countershock
Proxy
Ventricular Fibrillation
Angiotensin II
Antihypertensive Agents
Pharmacology
Blood Pressure
Morbidity
Phenotype
Mortality
Therapeutics
Pharmaceutical Preparations

Keywords

  • Angiotensin II receptor blockers
  • Atrial fibrillation
  • Left ventricular hypertrophy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hematology
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

@article{c2fbd4e8ea6a4c6a9a492313b02280aa,
title = "Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention",
abstract = "Left ventricular hypertrophy (LVH) and atrial fibrillation (AF) are strong predictors of cardiovascular (CV) morbidity and mortality, independently of blood pressure levels and other modifiable and nonmodifiable risk factors. The actions of circulating and tissue angiotensin II, mediated by AT1 receptors, play an important role in the development of a wide spectrum of cardiovascular alterations, including LVH, atrial enlargement and AF. Growing experimental and clinical evidence suggests that antihypertensive drugs may exert different effects on LVH regression and new onset AF in the setting of arterial hypertension. Since a number of large and adequately designed studies have found angiotensin II receptor blockers (ARBs) to be more effective in reducing LVH than beta-blockers and data are also available showing their effectiveness in preventing new or recurrent AF, it is reasonable to consider this class of drugs among first line therapies in patients with hypertension and LVH (a very high risk phenotype predisposing to AF) and as adjunctive therapy to antiarrhythmic agents in patients undergoing pharmacological or electrical cardioversion of AF.",
keywords = "Angiotensin II receptor blockers, Atrial fibrillation, Left ventricular hypertrophy",
author = "Cesare Cuspidi and Francesca Negri and Alberto Zanchetti",
year = "2008",
doi = "10.2147/vhrm.2008.04.01.67",
language = "English",
volume = "4",
pages = "67--73",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Angiotensin II receptor blockers and cardiovascular protection

T2 - Focus on left ventricular hypertrophy regression and atrial fibrillation prevention

AU - Cuspidi, Cesare

AU - Negri, Francesca

AU - Zanchetti, Alberto

PY - 2008

Y1 - 2008

N2 - Left ventricular hypertrophy (LVH) and atrial fibrillation (AF) are strong predictors of cardiovascular (CV) morbidity and mortality, independently of blood pressure levels and other modifiable and nonmodifiable risk factors. The actions of circulating and tissue angiotensin II, mediated by AT1 receptors, play an important role in the development of a wide spectrum of cardiovascular alterations, including LVH, atrial enlargement and AF. Growing experimental and clinical evidence suggests that antihypertensive drugs may exert different effects on LVH regression and new onset AF in the setting of arterial hypertension. Since a number of large and adequately designed studies have found angiotensin II receptor blockers (ARBs) to be more effective in reducing LVH than beta-blockers and data are also available showing their effectiveness in preventing new or recurrent AF, it is reasonable to consider this class of drugs among first line therapies in patients with hypertension and LVH (a very high risk phenotype predisposing to AF) and as adjunctive therapy to antiarrhythmic agents in patients undergoing pharmacological or electrical cardioversion of AF.

AB - Left ventricular hypertrophy (LVH) and atrial fibrillation (AF) are strong predictors of cardiovascular (CV) morbidity and mortality, independently of blood pressure levels and other modifiable and nonmodifiable risk factors. The actions of circulating and tissue angiotensin II, mediated by AT1 receptors, play an important role in the development of a wide spectrum of cardiovascular alterations, including LVH, atrial enlargement and AF. Growing experimental and clinical evidence suggests that antihypertensive drugs may exert different effects on LVH regression and new onset AF in the setting of arterial hypertension. Since a number of large and adequately designed studies have found angiotensin II receptor blockers (ARBs) to be more effective in reducing LVH than beta-blockers and data are also available showing their effectiveness in preventing new or recurrent AF, it is reasonable to consider this class of drugs among first line therapies in patients with hypertension and LVH (a very high risk phenotype predisposing to AF) and as adjunctive therapy to antiarrhythmic agents in patients undergoing pharmacological or electrical cardioversion of AF.

KW - Angiotensin II receptor blockers

KW - Atrial fibrillation

KW - Left ventricular hypertrophy

UR - http://www.scopus.com/inward/record.url?scp=41549153780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549153780&partnerID=8YFLogxK

U2 - 10.2147/vhrm.2008.04.01.67

DO - 10.2147/vhrm.2008.04.01.67

M3 - Article

C2 - 18629360

AN - SCOPUS:41549153780

VL - 4

SP - 67

EP - 73

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

IS - 1

ER -